MK-3475 (pembrolizumab)

pembrolizumab · Merck & Co.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-3475 (pembrolizumab), covering 2025-12-03 to 2025-12-03. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer [Phase 1]